Taxanes prodrug-based nanomedicines for cancer therapy
Author:
Publisher
Elsevier BV
Subject
Pharmaceutical Science
Reference227 articles.
1. Hypoxia and noncoding RNAs in taxane resistance;Pucci;Trends Pharmacol. Sci.,2018
2. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial;Zielinski;Lancet Oncol.,2016
3. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial;Pignata;Lancet Oncol.,2014
4. Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT);Vogel;BMC Cancer,2016
5. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial;Quoix;The Lancet,2011
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Dual role of triglyceride structures facilitates anti-tumor drug delivery: Both as a self-assembling module and a responsive module;Journal of Colloid and Interface Science;2025-01
2. A computer-aided, heterodimer-based “triadic” carrier-free drug delivery platform to mitigate multidrug resistance in lung cancer and enhance efficiency;Journal of Colloid and Interface Science;2025-01
3. Improved therapeutic index of the liposomal docetaxel-glutathione prepared by active click loading;European Journal of Pharmaceutics and Biopharmaceutics;2024-10
4. Recent developments in synthetic approaches for macromolecular prodrugs;Progress in Polymer Science;2024-08
5. Carbon-Spaced Tandem-Disulfide Bond Bridge Design Addresses Limitations of Homodimer Prodrug Nanoassemblies: Enhancing Both Stability and Activatability;Journal of the American Chemical Society;2024-08-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3